Can machine learning predict ABPA recurrence?
Part of Immune system & allergy, Infections, Lungs & breathing clinical trials.
This study uses a computer model to see if it can predict when ABPA (a lung condition) might come back. If you have ABPA and are stable after treatment, this could help doctors monitor you better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with ABPA based on current medical guidelines.
- Your ABPA is stable: either you are newly diagnosed and haven't had treatment, or you had a flare-up but got at least 50% better after treatment, with clear lung X-rays or a 20% drop in a blood marker called IgE.
- You do not have cancer, severe organ problems, active tuberculosis, or advanced heart, kidney, or liver disease.
- You are not pregnant, breastfeeding, or on long-term steroids or immune-suppressing drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study helps doctors predict whether allergic bronchopulmonary aspergillosis (ABPA)—a serious lung condition caused by fungal allergy—will come back after treatment. Researchers will analyze blood samples and immune system markers to identify patients at higher risk of relapse, which could improve how doctors monitor and treat you.
This study looks at how the presence of fungus in lung samples relates to the long-term outlook for people with allergic bronchopulmonary aspergillosis (ABPA). It aims to help doctors better understand the disease and guide treatment.
This study looks at why some people with asthma get a lung infection from mold called aspergillus. It will help doctors better understand the condition and how to treat it.
This study tests if biologic drugs are safe and effective for people with allergic bronchopulmonary aspergillosis (ABPA) who also have severe asthma. It may help if you've had an asthma attack in the past year.
This trial tests a procedure that uses a bronchoscope to clean mucus from the airways and then spray the antifungal drug amphotericin B directly into the lungs. It may help people whose ABPA is active and not improving with standard treatments.
This study looks at how well the drug tezepelumab works in treating allergic bronchopulmonary aspergillosis (ABPA), a lung condition caused by an allergic reaction to a common fungus. It may help reduce asthma symptoms and flare-ups in people with severe asthma related to ABPA.
Hear when a new ABPA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.